Psychedelics and virtual reality: parallels and applications

The extracted text does not report a formal methods section or a systematic search strategy. Instead, the paper appears to be a narrative synthesis that integrates findings from prior empirical studies, reviews, theoretical accounts, and naturalistic reports (including online community descriptions). Where quantitative comparisons are offered, the authors draw on previously published effect-size estimates from prior reviews and individual studies (for example, compiled effect sizes for psychedelic-assisted psychotherapy and separate meta-analytic results for VR interventions). The article also refers to specific technological developments (e.g. VR tools designed to mimic psychedelic visual phenomenology) and anecdotal data from online forums to illustrate current combined uses. Because no explicit inclusion/exclusion criteria, database list, or risk-of-bias assessment are reported in the extracted text, this work should be understood as a conceptual review rather than a systematic meta-analysis.

The paper organises empirical and conceptual material under several headings that together describe phenomenological, therapeutic, and practical parallels and intersections between psychedelics and VR. Phenomenological parallels: Both modalities are highlighted as capable of producing immersive alterations in visual perception and broader sense of immersion. DMT is emphasised for producing particularly vivid "visions" that can at high doses feel like alternate universes, while VR by design immerses users in visually constructed environments. Both have been used to elicit awe; psychedelic sessions (for example, with psilocybin) have been described by many participants as among the most meaningful experiences of their lives, and certain VR environments have been experimentally associated with increased perceived vastness, presence, and positive affect. Factors such as aesthetic beauty, social themes, familiarity, and personalisation influence awe in VR. Therapeutic overlaps and proposed mechanisms: The authors list common clinical targets for each approach, including depression, anxiety, obsessive–compulsive disorder (OCD), substance misuse, and end-of-life distress. Proposed mechanisms for psychedelics include mystical-type or emotionally salient experiences, ego-dissolution, enhanced neuroplasticity/neurogenesis (e.g. increased BDNF), and reductions in default mode network (DMN) activity; VR's therapeutic effects are attributed largely to immersion and presence, the ability to provide safe simulated exposures, and facilitation of memory reconsolidation. The paper argues that both approaches may promote therapeutic change by transiently disrupting rigid self-related narratives and habitual patterns of cognition. Comparative effect-size summaries: The extracted text provides previously compiled effect sizes for psychedelics and for VR interventions. For long-term changes in depression following psychedelic-assisted psychotherapy, reported effect-size ranges include ηp2 = 0.32–0.70, Hedges' g = 0.7–3.2, and Cohen's d = 0.82–2.3. For VR therapy for depression, one review yielded an average Cohen's d = 0.67 (derived from two studies), and another VR intervention combining self-compassion training reported Cohen's d = 1.11. For anxiety outcomes after psychedelic treatment, reported effect sizes ranged from ηp2 = 0.27–0.28, Hedges' g = 2.0–3.2, and Cohen's d = 0.5–2.67. Regarding VR for anxiety, one review reported Cohen's d = 1.11 versus waitlist controls but d = 0.16 when compared with traditional evidence-based treatments. The authors note that data for substance misuse, OCD, and end-of-life care remain limited, making direct comparisons tentative. Safety and adverse effects: Psychedelics are described as non-toxic to organ systems with low abuse potential, but they can provoke psychologically challenging acute reactions; the authors report that up to one-third of participants may experience transient fear or panic during high-dose sessions. Individuals with psychosis vulnerability are typically excluded from trials. A pharmacological risk is highlighted for combinations that can produce serotonin syndrome—for example, combining SSRIs with MAOIs such as those present in ayahuasca—so some retreat settings require medication washout. VR-related risks noted include nausea, dizziness, and the possibility of seizures in people with epilepsy. The authors also emphasise that ratings of immersion and presence in VR predict therapeutic outcomes. Combined and naturalistic uses: Recreationally, many users report combining psychedelics and VR to enhance immersion; the authors cite online communities (for example a Reddit forum with around 6000 members at the time of writing) where anecdotal reports describe heightened presence in virtual worlds while under psychedelics. Experimentally and clinically, the text discusses potential applications such as using VR to simulate psychedelic visual phenomenology to prepare hallucinogen‑naïve participants, employing VR to recreate natural environments (which are sometimes inaccessible in clinical settings) to support sessions, and systematically manipulating virtual settings to study "setting" effects. The paper mentions specific VR technology (developed by Suzuki and colleagues) that aims to reproduce psychedelic-like visual effects.

The authors interpret the overlaps between psychedelics and VR as indicating common capacities to transiently alter perspective and disrupt rigid patterns of thought, which may underlie their similar transdiagnostic therapeutic uses. They propose that VR could function pragmatically as a preparatory tool for participants, as a means to tailor and optimise the therapeutic setting during psychedelic sessions, and as an experimental platform to manipulate environmental variables reproducibly. Important limitations and ethical considerations are discussed. The paper notes cultural sensitivities: some communities regard psychedelic experiences as sacred and may resist adding technological devices to these practices, so researchers should proceed respectfully. A phenomenological distinction between internally generated perceptual changes (psychedelics) and externally generated ones (VR) is emphasised; this difference could affect perceived authenticity or noetic quality of experiences and may have safety implications for individuals with psychotic conditions characterised by internal/external misattribution. The authors also acknowledge that current VR cannot yet replicate all nuances of psychedelic phenomenology—synesthetic experiences in particular require further development. The discussion identifies open empirical questions and priorities for future research: systematic testing of combined psychedelic/VR interventions, investigation of whether different psychedelic compounds interact differently with VR environments, determination of which virtual environments best support therapeutic goals, and exploration of shared neural mechanisms (for example, whether VR can modulate DMN activity in ways analogous to psychedelics and potentially induce aspects of ego dissolution). Safety, cultural acceptability, and careful experimental design are underscored as necessary considerations before clinical implementation.

The paper concludes that psychedelics and VR share multiple phenomenological and practical connections: both can alter sensory experience, elicit awe, and be used alongside psychotherapy to treat a range of psychiatric conditions. VR may be useful for preparing participants for psychedelic sensory distortions, for simulating therapeutic settings (including natural environments inaccessible in clinical sites), and for tailoring experiences during sessions. Recreational co-use is already widespread in online communities, and the authors suggest that systematic research into the interaction of technology and psychopharmacology could yield important insights for mental-health research and practice.